DANCANN PHARMA A/S: Financial statements 2021
CVR: 39426005
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
DANCANN PHARMA A/S (CVR 39426005) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK -6,773,000 and a net result of DKK -11,750,000 compared with DKK -4,254,612 the year before. Equity in the 2021 report amounted to DKK 53,370,000. The solvency ratio was 78.4%. The company had 10 employees in the financial year.
- Revenue
- DKK 0
- Gross Profit
- DKK -6,773,000
- Profit/Loss
- DKK -11,750,000
- Equity
- DKK 53,370,000
- Total Assets
- DKK 68,102,000
- Employees
- 10
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | 0 | -6.8 mio. | -11.8 mio. | 53.4 mio. | 10 |
| 2020 | - | -4.8 mio. | -4.3 mio. | 44.3 mio. | 4 |
| 2019 | - | -422 t. | -1.2 mio. | -1.4 mio. | 4 |
Official annual report
Find more companies like DANCANN PHARMA A/S
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2021
DANCANN PHARMA A/S has published its annual report for 2020. Gross profit came to DKK -4,829,650, and the net result was DKK -4,254,612.
As of April 28, 2021, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of DANCANN PHARMA A/S.
As of April 28, 2021, A/S PSE 17 NR. 1056 has stepped down as auditor of DANCANN PHARMA A/S.
As of April 28, 2021, Christian Carlsen has joined the board of directors of DANCANN PHARMA A/S.
As of March 19, 2021, Carsten Trads has joined the board of directors of DANCANN PHARMA A/S.
As of March 19, 2021, Magnus Østergaard Dahlmann has joined the board of directors of DANCANN PHARMA A/S.
As of March 18, 2021, Carsten Trads has left the board of directors of DANCANN PHARMA A/S.
As of March 18, 2021, Magnus Østergaard Dahlmann has left the board of directors of DANCANN PHARMA A/S.
About DANCANN PHARMA A/S
DANCANN PHARMA A/S is a Danish company of the type Aktieselskab based in Ansager, founded in 2018. The company is under bankruptcy. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named DANCANN PHARMA ApS and DANCANN PHARMA IVS. The company is owned by JEQ Capital AB. The company has 1 employee (2026). In 2024, the company reported a gross profit of DKK -148,000 and a net result of DKK -8,346,000 compared with DKK -62,260,000 the year before. Equity in the 2024 report amounted to DKK 14,620,000.